Baltimore biotechnology firm WindMIL Therapeutics has raised a $32.5 million to support clinical trials and further development for new cancer therapies.
Baltimore biotechnology firm WindMIL Therapeutics has raised a $32.5 million to support clinical trials and further development for new cancer therapies.